VERTEX PHARMACEUTICALS INC / MA Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q2 2024.
  • Vertex Pharmaceuticals Inc / Ma Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.59B, a 492% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$490M, a 115% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Net Income (Loss) Attributable to Parent for 2023 was $3.62B, a 8.96% increase from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Net Income (Loss) Attributable to Parent for 2022 was $3.32B, a 41.8% increase from 2021.
  • Vertex Pharmaceuticals Inc / Ma annual Net Income (Loss) Attributable to Parent for 2021 was $2.34B, a 13.6% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$490M -$3.59B -$4.51B -492% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $4.02B $1.1B +$400M +57.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $3.62B $969M +$150M +18.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $3.47B $1.04B +$105M +11.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $3.36B $916M +$105M +13% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 $3.26B $700M -$62.3M -8.18% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $3.32B $819M +$48.8M +6.34% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $3.27B $931M +$78.6M +9.23% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $3.19B $811M +$744M +1110% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $2.45B $762M +$109M +16.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $2.34B $770M +$166M +27.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $2.18B $852M +$184M +27.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $1.99B $67M -$770M -92% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $2.76B $653M +$50.3M +8.35% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $2.71B $604M +$21M +3.59% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $2.69B $667M +$610M +1060% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $2.08B $837M +$570M +213% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $1.51B $603M +$334M +124% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $1.18B $583M -$967M -62.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $2.14B $57.5M -$71.2M -55.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $2.22B $267M +$60.1M +29% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $2.16B $269M +$58.4M +27.8% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $2.1B $1.55B +$1.45B +1440% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $647M $129M +$232M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $415M $207M +$189M +1052% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 $226M $210M -$37.5M -15.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $263M $101M +$67.7M +206% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-13
Q3 2017 $196M -$103M -$64.1M -165% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-13
Q2 2017 $260M $18M +$82.5M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-13
Q1 2017 $177M $248M +$289M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-13
Q4 2016 -$112M $32.9M +$107M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$219M -$38.8M +$56.3M +59.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 -$275M -$64.5M +$124M +65.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 -$399M -$41.6M +$157M +79% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 -$556M -$73.7M +$103M +58.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 -$659M -$95.1M +$74.9M +44.1% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 -$734M -$189M -$29.5M -18.5% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 -$705M -$199M +$33.9M +14.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 -$739M -$177M -$221M -499% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-16
Q3 2014 -$518M -$170M -$45.9M -37% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-16
Q2 2014 -$472M -$159M -$102M -179% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-16
Q1 2014 -$369M -$232M +$75.6M +24.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-16
Q4 2013 -$445M $44.3M +$120M Oct 1, 2013 Dec 31, 2013 10-K 2015-02-13
Q3 2013 -$565M -$124M -$66.6M -116% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-13
Q2 2013 -$499M -$57.2M +$7.77M +12% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-13
Q1 2013 -$507M -$308M -$400M -436% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-13
Q4 2012 -$107M -$76.1M -$235M -148% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-11
Q3 2012 $128M -$57.5M -$279M -126% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-11
Q2 2012 $406M -$64.9M +$109M +62.7% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-11
Q1 2012 $297M $91.6M +$268M Jan 1, 2012 Mar 31, 2012 10-K 2014-02-11
Q4 2011 $29.6M $159M +$339M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$309M $221M +$430M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 -$740M -$174M +$25.9M +13% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 -$765M -$176M -$10.8M -6.55% Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q4 2010 -$755M -$180M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-22
Q3 2010 -$209M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-22
Q2 2010 -$200M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-22
Q1 2010 -$165M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.